科技日报北京11月4日电 （记者张梦然）据发表在新一期《科学进展》上的一项研究，瑞士苏黎世 联邦理工学院团队在模拟太空微重力的条件下，利用3D打印技术制造出结构精确的人体肌肉组织。这 种高保真度的组织模型对于研究疾病机制、测试新药至关重要，也为太空生物制造和人类健康研究开辟 了新路径。 科学家首次在类似太空的失重环境中成功制造出了活的人体肌肉组织。在地球上打印活体组织其实 非常困难，重力会导致未固化的"生物墨水"下垂、变形甚至坍塌。此次，科研人员通过一种特殊的"抛 物线飞行"来创造短暂的失重环境，成功完成3D打印实验。未来，我们可以在太空环境中建立"生物实 验室"，进一步培养人体组织。这些高保真肌肉模型，能帮我们更精准地模拟肌肉萎缩疾病或衰老过 程，加速相关新药的研发和测试。 这项技术的成功标志着空间组织工程的重要进展。团队的长期目标是在空间站或未来的轨道实验室 直接培育人类组织和类器官。 在太空中制造的这些"迷你器官"不仅能用于研究失重引发的肌肉退化，还可作为研究肌萎缩等疾病 的平台。更重要的是，微重力下打印的组织结构更接近真实人体，能为药物测试提供更准确的评估环 境，从而加速新疗法的开发。这一突破不仅服务 ...

Market Overview - On November 4, 2025, the A-share market saw all three major indices decline, with the Shanghai Composite Index closing at 3960 points, down 0.41%. The Shenzhen Component Index fell 1.71% to 13175 points, and the ChiNext Index dropped 1.96% to 3134 points. Over 3600 stocks declined, with total trading volume in the Shanghai and Shenzhen markets at 1.92 trillion yuan, a decrease of 190 billion yuan from the previous trading day [1] - The Hong Kong market also experienced a downturn, with the Hang Seng Index closing at 25952.4 points, down 0.79% or 205.96 points. The Hang Seng China Enterprises Index fell 0.92% to 9173.21 points, and the Hang Seng Tech Index decreased by 1.76% to 5818.29 points, with total trading volume at 239.986 billion HKD [1] - In the U.S. market, all three major indices fell, with the S&P 500 Index down 1.17% to 6771.55 points, the Nasdaq Composite Index down 2.04% to 23348.64 points, and the Dow Jones Industrial Average down 0.53% to 47085.24 points [1] New Stock Listing - On November 4, 2025, a new stock, Fengbei Biological (stock code 603334), was listed with an issue price of 24.49 yuan per share and a price-to-earnings ratio of 30.47. The company specializes in the comprehensive utilization of natural oil resources, focusing on bio-based materials and biofuels, with applications in various fields such as pesticides, fertilizers, and biomedicine [1] Important Regulatory News - On November 4, 2025, the People's Bank of China announced a 700 billion yuan reverse repurchase operation scheduled for November 5, 2025, to maintain ample liquidity in the banking system. The operation will have a term of three months (91 days) [2] - The National Medical Products Administration released a new version of the "Quality Management Standards for Medical Device Production," which will take effect on November 1, 2026. This revision aims to enhance the quality management system of medical device companies and improve the overall quality management level in the medical device industry [2]

Core Insights - Baoding Haizel Biotechnology Co., Ltd. has recently been established with a registered capital of 100,000 RMB and is led by legal representative Yang Jianan [1] Company Overview - The company operates in various sectors including technology services, pet services, pet sales, and pet food wholesale and retail [1] - It also engages in livestock sales, feed additive sales, and sales of specialized equipment for feed production [1] - The company is involved in internet sales (excluding licensed goods), arts and crafts sales (excluding ivory products), and experience-based expansion activities [1] Business Activities - The company provides a wide range of services such as conference and exhibition services, educational consulting (excluding licensed training activities), and popular science promotion services [1] - It offers information consulting services (excluding licensed information consulting), brand management, and zoo management services [1] - The company is also engaged in food sales (only pre-packaged food), aquarium management services, and leisure sightseeing activities [1] Additional Services - The company provides park and scenic area management, amusement park services, and management of tourism development project planning and consulting [1] - It is involved in the development and operation of rural folk crafts and products, leisure agriculture, and rural tourism resources [1] - The company has licensed activities including animal diagnosis and tourism business, which require approval from relevant authorities before operation [1]

十月二十九日，直达韩国仁川港的"泛奥升奥普轮"（右）在青岛港前湾港区装卸集装箱（无人机照 片）。新华社记者 李紫恒摄 10月30日至11月1日，国家主席习近平应邀赴韩国庆州出席亚太经合组织（APEC）第三十二次领导人 非正式会议并对韩国进行国事访问。 连日来，旅居韩国的华侨华人持续热议APEC会议上的中国声音。在接受本报记者采访时，多位侨胞分 享了亲身参与双多边合作的经历，对即将到来的APEC"中国年"满怀期待，表示将继续发挥侨力，为中 韩合作架桥、为亚太发展添彩。 关注APEC会议释放积极信号 除传统贸易与投资外，中韩在人工智能、新能源、文化旅游、生物科技等领域的合作活力日益凸显 最近，韩国浙江商会会长、全博集团董事长张益波完成了一项重要签约——与韩中总商会签署全面合作 协议。其中，储能储电等新能源技术是双方合作的一个重点。 本次APEC会议上，中方提出强化数智赋能、坚持绿色低碳、落实普惠共享等主张，给张益波留下了深 刻印象，也坚定了他继续推进绿色及高新技术产业合作的信心。目前，他正全力筹备浙江专精特新"小 巨人"企业代表团赴韩考察事宜。"考察团将走访韩国多家科技企业及高校，对接新能源、智能制造等领 域的先 ...

Core Insights - Hebei Yexiu Benlan Biotechnology Co., Ltd. has been established with a registered capital of 3 million RMB [1] Company Overview - The legal representative of the company is Shi Huixin [1] - The business scope includes general projects such as technology services, development, consulting, and transfer [1] - The company also offers health consulting services (excluding medical treatment), wellness services (non-medical), brand management, marketing planning, and enterprise management consulting [1] Business Activities - The company is involved in personal internet live streaming services, wholesale and retail of cosmetics, personal hygiene products, daily chemical products, and daily necessities [1] - It is permitted to provide beauty services, subject to approval from relevant authorities [1]

11月4日，第138届中国进出口商品交易会（以下简称"广交会"）在广州圆满落幕。根据广交会官方微信 公众号内容，本届广交会共有来自223个国家和地区的超31万名境外采购商到会，较第137届广交会增长 7.5%，再创历史新高。 其中，共建"一带一路"国家采购商21.4万人，增长9.4%，占比69%。欧盟、中东、美国、巴西采购商增 长明显，增幅分别为32.7%、13.9%、14%、33.2%。158家工商机构组团参会，增长12%。550个采购团 中，美国塔吉特、法国家乐福、日本似鸟等406家头部企业组团参会，增长7.9%。 不少采购商表示，广交会既是一站式采购平台，也是洞察行业趋势的风向标。 本届广交会现场意向出口成交256.5亿美元，保持增长势头。与共建"一带一路"国家出口成交占比超六 成，传统市场成交保持稳定。展位前涌动的不仅是采购商的"流量"，也是订单的"增量"与合作的"留 量"，洽谈区座无虚席，全球采购商穿梭于各展位，寻觅心仪产品与合作机遇。 第138届广交会上，中国制造正以多元、立体的形象，向世界展示其不仅拥有突破创新的硬核科技实 力，也兼备深入生活细节的"精细"基因。广交会的火热见证着中国智造从"跟跑 ...

Core Points - The meeting between Chinese Premier Li Qiang and Nigerian Speaker Tajuddin highlights the deep traditional friendship and partnership between China and Nigeria, emphasizing the rapid development of bilateral relations into a comprehensive strategic partnership [1][2] - Both countries, as developing nations with large populations and significant development potential, are encouraged to strengthen cooperation in various sectors, including trade, investment, agriculture, mining, infrastructure, and emerging industries like clean energy and artificial intelligence [2][3] Group 1 - China and Nigeria are committed to enhancing their cooperation through initiatives such as the "Ten Cooperation Actions" and the Belt and Road Initiative, aiming for high-quality economic partnerships and zero-tariff measures [2] - Nigeria expresses strong support for China's sovereignty and territorial integrity, indicating a mutual respect and support that has characterized their relationship since diplomatic ties were established [3] Group 2 - The meeting underscores the importance of multilateral cooperation, with both countries aiming to coordinate efforts in global platforms like BRICS, the United Nations, and the World Trade Organization to promote a more just and equitable global governance system [2][3] - The Nigerian Parliament is committed to supporting and facilitating cooperation across various fields, aiming to elevate the comprehensive strategic partnership to new heights [3]

Investment Rating - The report maintains a "Hold" rating for the company, with target prices set at HKD 75 for the Hong Kong stock and RMB 96.7 for the A-share [1][8]. Core Insights - The company reported a revenue of RMB 620 million in Q3 2025, representing a year-on-year increase of 33.1% and a quarter-on-quarter increase of 8.7%. The net loss attributable to shareholders narrowed to RMB 100 million, a decrease of 65.2% year-on-year and 48.3% quarter-on-quarter, slightly better than expectations [2][3]. - The gross margin for Q3 2025 was 84.6%, showing a year-on-year increase of 3.1 percentage points, while R&D expenses decreased by 29.9% year-on-year [2][3]. - The commercialization performance of the drug TaiTasi was slightly better than expected, with sales of RMB 380 million in Q3 2025, up 41.4% year-on-year. The drug VidiXimab achieved sales of RMB 240 million, up 21.4% year-on-year [3][4]. Financial Performance Summary - For the full year, the company expects a reduction in losses of approximately 50%, consistent with previous guidance. The revenue forecast for 2025 is RMB 2.889 billion, with a year-on-year growth of 68.9% [2][9]. - The net loss for 2025 is projected to be RMB 130 million, with a return to profitability expected in 2026 with a net profit of RMB 91 million [9][10]. - The company’s total market capitalization is approximately HKD 57.3 billion, with a recent average trading volume of HKD 681 million over the past three months [4][6]. Product Pipeline and Market Outlook - The company is focusing on the development of RC148 (PD-1/VEGF) for NSCLC, with plans to prioritize its clinical trials. The management has observed promising efficacy and safety in early trials [4][8]. - The ongoing national medical insurance negotiations for TaiTasi and VidiXimab are crucial, as moderate price reductions could positively impact stock performance [3][4].

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 3.0% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 2.8% [1] - The CSI Innovative Drug Industry Index declined by 2.3% [1] Group 2 - The CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index both dropped by 1.8% [1] - Despite the market downturn, there was a significant net subscription for the Hang Seng Innovative Drug ETF (159316) and the Biotechnology ETF (159837), with net subscriptions reaching 44 million units and 40 million units respectively [1]

Group 1 - The core point of the news is that a block trade of YingTai Bio (stock code: 920819) occurred on November 4, with a transaction volume of 200,000 shares and a transaction amount of 840,000 yuan, at a price of 4.20 yuan, which is a 2.10% discount compared to the closing price of the day [2][3] - In the past month, there have been a total of 9 block trades for this stock, with a cumulative transaction amount of 6.5876 million yuan [3] - The closing price of YingTai Bio on the day of the report was 4.29 yuan, reflecting a decrease of 2.94%, with a daily turnover rate of 1.14% and a total transaction amount of 59.4166 million yuan [3] Group 2 - YingTai Bio was established on July 1, 2005, with a registered capital of 1.2258 billion yuan [3] - The buyer and seller of the block trade were both from CITIC Securities Co., Ltd., Beijing Anwai Dajie Securities Branch [2]